Immunological biomarker for predicting clinical effect of cancer
AssigneeSaitama Medical University
InventorHiroshi Kagamu
Life of this patent
Estimating the term…
Abstract
The present invention relates to the prediction of responsiveness to cancer immunotherapy of a subject based on the T-cell composition of the subject, and a therapeutic method using cancer immunotherapy based on the prediction. The present invention also provides a method for improving or maintaining responsiveness to cancer immunotherapy of a subject. Responsiveness to cancer immunotherapy is predict by determining a relative value of a CD4. T-cell subpopulation, dendritic cell subpopulation, and/or CD8+ T-cell subpopulation correlated with a dendritic cell stimulation in an anti-tumor immune response in a sample derived from a subject. A composition for treating or preventing cancer comprising cells such as CD62LlowCD4+ T-cells is also provided.
Claims21
-52. (canceled)
A method of predicting a response to cancer immunotherapy of a subject, the method comprising:
- measuring an amount of CD4+CD62Llow T-cells of the subject (X);
- measuring an amount of CD4+Foxp3+CD25+T-cells of the subject (Y);
- and
- comparing a relative value of X to Y with an ineffective group threshold value, thereby predicting that the subject is not a part of an ineffective group to the cancer immunotherapy.
Dependencies are inferred from the claim text.